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Nephrotic syndrome remains the most common manifestation of glomerular disease in childhood. Minimal change
nephropathy is the most common cause of the syndrome in children. Despite its initial high response rate to
corticosteroids and its favorable prognosis, relapses are common leading to increased morbidity and cost of treatment.
This review seeks to appraise the common triggers of relapse and to highlight the evolving hypotheses about the
pathogenesis of the syndrome. Literature search was conducted through PubMed, Google web search and Cochrane
Database of Systematic reviews using relevant search terms.
Acute respiratory infections and urinary tract infections are the most frequent infectious triggers of relapse. Targeted
interventions like initiating corticosteroid or its dose-adjustment during episodes of acute respiratory infection and
zinc supplementation are reportedly effective in reducing relapse rates. Hypotheses on pathogenesis of the syndrome
have evolved from the concepts of ‘immune dysregulation’, ‘increased glomerular permeability’ to ‘podocytopathy’.
Although development of drugs which can regulate the pathways for podocyte injury offers future hope for
effective and targeted treatment, the relapse-specific interventions currently contribute to significant reduction in
disease morbidity.
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Nephrotic syndrome refers to the tetrad of edema,
‘nephrotic- range’ proteinuria, hypoalbuminemia, and hy-
perlipidemia. Nephrotic- range proteinuria in the pediatric
age group is defined as protein excretion of more than
40 mg/m2/hour. In children, 24 hour-urine collections are
unreliable. Thus, a single, first morning urine sample is
now preferably used to quantify protein excretion by the
estimation of the urine protein/creatinine ratio [1]. From
the new management guidelines released by the Kidney
Disease: Improving Global Outcomes (KDIGO) group,
urine protein/creatinine ratio of ≥ 2000 mg/g correlates
with ‘nephrotic-range’ proteinuria or dip-stick proteinuria
of 3+ [2].
Nephrotic syndrome remains the most common
manifestation of glomerular disease in childhood [3].
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unless otherwise stated.(ISKDC) noted in a report that the vast majority of
pre-adolescent children with idiopathic nephrotic syn-
drome had minimal change nephropathy (MCN) on renal
biopsy [4]. This histological subtype is the most common
cause of nephrotic syndrome in children [5]. More than
90% of children with minimal change nephropathy achieve
remission with oral corticosteroids and thus have steroid-
sensitive nephrotic syndrome (SSNS) [6,7]. By contrast,
the majority of children with the second most common
histological subtype- focal segmental glomerulosclerosis
(FSGS) - do not respond to corticosteroids. Only 20% re-
spond to the medication with a high risk of developing
end-stage renal failure [5,8].
Despite the initial response rate of 90% to 95% and the
favorable prognosis in children with SSNS, relapses
occur in 60% to 90% of the initial responders which
can lead to increased morbidity, complications and de-
creased quality of life [7,9,10]. The disease progresses to
frequent relapses, often accompanied by steroid depen-
dence in about 20% to 60% of patients [11]. Relapses areThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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sepsis, thrombosis, dyslipidemia and malnutrition [12],
while treatment with high-dose prednisolone is asso-
ciated with significant adverse effects like hip avascular
necrosis, hypertension, diabetes and behavioral disorders
[13]. These challenges in management have led to the use
of various long-term immunosuppressive and steroid-
sparing strategies to reduce the frequency of relapses
which include long-term, low-dose alternate day pred-
nisolone, cyclophosphamide, levamisole, calcineurin in-
hibitors such as cyclosporine A (CsA) or tacrolimus,
mycophenolate mofetil (MMF) and rituximab.
It is currently recognized that at least 50% of relapses
are triggered by a viral upper respiratory tract infection
[14-16]; which may be linked to non-specific host re-
sponse to infection (cytokine release) rather than to viral
antigen or antibody response [15]. Thus, other infections
such as urinary tract infection (UTI), diarrhea, perito-
nitis and skin infections have also been implicated [14].
Studies have established the role of UTI as an important
cause of relapse, as well as the cause of poor response to
steroid therapy [17-19]. Based on these reports which
have identified specific triggers of relapse, targeted inter-
ventions have been shown to alter disease morbidity.
Interestingly, the recent KDIGO Summary of Recom-
mendation statements in the clinical practice Guideline
for Glomerulonephritis advises “that daily prednisolone
be given during episodes of upper respiratory tract and
other infections to reduce the risk for relapse in children
with frequently relapsing and steroid dependent SSNS
already on alternate day prednisolone” [20].
This review seeks to appraise the triggers of relapse, as
well as to highlight the evolving hypotheses about the
pathogenesis of nephrotic syndrome.
Literature search: strategy and outcome
Literature search was conducted through PubMed,
Google web search and Cochrane Database of Systematic
reviews over a period of six months (July to December,
2014). Using a combination of the following search terms
‘nephrotic syndrome in children’, ‘pathogenesis’, ‘triggers
of relapse’, ‘zinc supplementation’, ‘steroid use in preven-
ting relapse’ and ‘immunosuppressive drugs’, the search
yielded 6,060 results by Google, 145 results by PubMed
and 11 Cochrane reviews. Prospective and retrospective
studies relevant to the objectives of the review and pub-
lished in peer-reviewed journals were subsequently se-
lected. Information was also gathered from textbooks
published within the past ten years.
Pathogenesis of nephrotic syndrome: evolving
hypotheses
The pathogenesis of nephrotic syndrome remains in-
completely resolved despite the strong evidence ofimmune dysregulation, mainly involving cell-mediated
immunity. The tendency of the disease to manifest and
relapse after viral infections or an atopic episode, the as-
sociation with HLA antigens and Hodgkin’s lymphoma,
and the therapeutic response to steroids and cyclospor-
ine support the ‘immune dysregulation’ hypothesis [21].
In fact, abnormalities of T cell subsets and/or function
have been reported in a number of patients with mini-
mal change nephropathy [22-24].
Antigen presentation to T lymphocytes leads to a polar-
ized immune response namely type 1(dominated by inter-
leukin 2) and type 2 (dominated by interleukins 4, 10 and
13). Type 1 cytokines predominate in cell-mediated im-
munity and type 2 cytokines in atopy and class-switching
of B-cells for production of IgG4 and IgE [25]. The fin-
dings of increased plasma levels of IgE, relatively normal
IgG4 and association with atopy suggest type 2 cytokine
bias in patients with minimal change nephropathy [21].
Increased systemic production of representative cytokines,
chiefly interleukin-4 is also reported while in vitro studies
suggest that podocytes express receptors for interleukin-4
and interleukin-13; activation of these receptors by the re-
spective cytokines might disrupt glomerular permeability
resulting in proteinuria [26].
Another hypothesis that evolved was the role of a sys-
temic circulating factor which might result in increased
glomerular permeability in patients with minimal change
nephropathy and focal segmental glomerulosclerosis [21].
Various vascular permeability factors have been implicated
including vascular endothelial growth factor, heparanase
and hemopexin [27]. Heparanase is thought to increase
the permeability of glomerular capillary wall by breaking
down heparin sulphate glucosaminoglycans. This degrad-
ation has long been postulated as a cause of increased
glomerular permeability to proteins [28].
However, recent evidence suggests that the primary
defect in idiopathic nephrotic syndrome might be at the
level of podocytes (the glomerular visceral epithelial
cell). Conventional immunosuppressive agents like
glucocorticoids and CsA are now known to directly
affect podocyte structure and function; challenging the
“immune theory” of the pathogenesis of childhood
nephrotic syndrome and portraying the disease as a
‘podocytopathy’ [29]. Injury to the podocyte can indeed
occur in many immunological and non-immunological
diseases of the kidney. Acquired podocytopathies like
idiopathic MCN and FSGS are considered as immuno-
logical diseases.
A hypothesis to unify these concepts of immune dys-
regulation, increased glomerular permeability and podo-
cytopathy is yet to be proposed [21], but the speculation
that critical podocyte proteins are probably potential tar-
gets for T cell cytokines or vascular permeability factors
still needs further confirmation [24,27].
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both in the maintenance of the glomerular filtration
barrier and structural integrity, as its injury and loss
contribute to proteinuria and progressive sclerosis [30].
Immunosuppressive agents such as corticosteroids and
calcineurin inhibitors (CsA and tacrolimus) are known
to have direct effects on podocytes through regulation of
some cytokines and several signaling pathways relevant
for stabilizing their actin cytoskeleton, cell maturation
and survival [30]. These non-immunological actions thus
protect the podocyte against injury and loss resulting in
their anti-proteinuric effect in nephrotic syndrome.
Although the pathogenic mechanism for nephrotic
syndrome has traditionally focused on dysregulation of
T cells, there is increasing evidence that B cells also play
a role given the efficacy of rituximab in treating the
disorder [31]. Rituximab is a chimeric monoclonal anti-
body against the CD 20 receptors on B cells initially
used for depletion of B cells in a variety of neoplastic
and immune-mediated disorders [32], but was first re-
ported to treat a child with nephrotic syndrome in 2004
[33]. In steroid-dependent or resistant cases, partial or
complete remission rates of 70-85% are documented
with many patients able to stop their immunosuppres-
sive medications [31]. The exact mechanism of action
remains unclear but it has been proposed that induction
of regulatory T cells may lead to a late effect on decrea-
sing proteinuria long after completion of therapy [34].
Current evidence from observational studies suggests
that rituximab can induce the remission of nephrotic
syndrome in patients with membranous nephropathy
[35-37], MCN [33,38,39], and FSGS [40,41].
Relapse: common triggers and targeted interventions
The common patterns of relapse in SSNS include infre-
quent relapses (1 relapse in 6 months or 1–3 relapses in
12 months) [2]; frequent relapses (2 or more relapses in
6 months of initial response or 4 or more relapses in any
12 month-period); and steroid dependence (2 consecu-
tive relapses during steroid therapy or within 2 weeks of
its cessation) [2,42,43]. About 50%-60% of children with
SSNS have frequent relapses or steroid dependence.
Factors documented as predictors of frequent relapses
include age younger 3 years at onset, delayed time to re-
mission (after 7–9 days), occurrence of an early relapse
(in the first 6 months after initial treatment) and short
initial therapy [43-49].
Identification of triggers of relapse in SSNS has led to
targeted interventions which aim to ameliorate disease
morbidity. An appraisal of studies on the subject shows
the prime role of infections in causing relapse [14-19]
although one of the studies has also reported school
events and up-coming hospital visits as triggers [16].
Amongst the infectious triggers, respiratory tract infectionconsistently ranks as the most prominent and fre-
quent factor irrespective of geographical setting [14-16,50]
(Table 1). However, urinary tract infection assumes a more
frequent role in other studies [17-19].
In these studies [14-16], the average prevalence rate of
respiratory tract infection as a trigger of relapse was
approximately 66.9%. It is note-worthy that two of the
studies were prospective [15,50], while the rest were
retrospective [14,16] with their obvious limitations. It is
therefore not surprising that the KDIGO recommenda-
tion of initiating daily prednisolone during episodes of
upper respiratory infections is tagged with a low quality
of evidence (grade C) [20].
Nevertheless, prospective interventional studies indi-
cate that relapses are significantly reduced when the
maintenance doses of corticosteroids are increased at
the onset of viral upper respiratory infections [51,52], or
when daily corticosteroids are given during onset of viral
upper respiratory infections [50,53]. To underscore the
importance of respiratory infections as triggers of re-
lapse, zinc supplementation has also been found to re-
duce relapses in children with SSNS [54,55], based on
the documented role of zinc in preventing these infec-
tions in children [56,57].
In the non-blind, randomized controlled trial conducted
in a tertiary health-care setting by Gulati et al. [50], 100
children aged 1 to 16 years with recently diagnosed idio-
pathic frequently relapsing nephrotic syndrome were
studied and were eligible for therapy with long-term,
alternate-day prednisolone (0.5 mg-0.75 mg/kg) with or
without levamisole (2 mg/kg). They were randomized to
either receive their usual alternate-day prednisolone daily
for 7 days during intercurrent infections (intervention
group) or continue alternate-day prednisolone (control
group). Sixty eight patients were treated with alternate-
day prednisolone alone while 32 patients received alternate-
day prednisolone and levamisole. At the 12-month
follow-up, there were 44 relapses (31 infection-associated)
in the intervention group as compared with 76 relapses
(56 infection-associated) in the control group. Patients
in the intervention group showed significantly lower
infection-associated relapse rates and lower total relapse
rates (Table 2). There was no increase in steroid toxicity:
cushingoid features were seen in 4 patients (intervention
group) and 5 patients (control group) while 2 patients de-
veloped cataract.
In another prospective study by Mattoo and colleague
[51], 36 children with steroid-dependent, relapsing neph-
rotic syndrome were placed on a maintenance alternate-
day prednisolone therapy of 0.5 mg/kg. The patients
were prospectively divided into two groups with compar-
able age and sex distribution. Group 1 patients were ad-
vised to take daily prednisolone for 5 days starting at the
time of the onset of an upper respiratory infection.
Table 1 Comparison of study findings on common triggers of relapse in SSNS in children
Country Triggers Frequency (%) Study
-Pakistan (Asia) -Infections −62.9% Moorani KN [14]






-Canada (N. America) -ARI (URI) −69.0% McDonald N et al. [15]
-no ARI (URI) −31% (prospective study)
-Japan (Asia) -ARI (URI) −52% Takahashi S et al. [16]
-School events −18% (retrospective study)
-Others −30%
-India (Asia) -URIc −92% -Gulati A et al. (2011) [50]
-Gastroenteritis −6% (prospective study)
-Fever without localized signs −2%
aARI-acute respiratory infections; bUTI-urinary tract infections; cURI-Upper respiratory infections.
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one during episodes of upper respiratory infection. At
the end of the 2 year follow-up period, the total number
of relapses in group 1 was 40 with a mean of 2.2 ± 0.87
per patient as compared with 99 relapses with a mean of
5.5 ± 1.33 per patient in group 2.
Furthermore, Abeyagunawardena and co-worker [52]
conducted a randomized, double-blind, placebo-controlled
crossover trial of 40 sequential patients receiving low-dose
prednisolone (<0.6 mg/kg) on alternate days as mainten-
ance therapy. At the first sign of a presumed viral upper
respiratory tract infection, the children were examined and
randomly allocated to take medicine A or B containing
either prednisolone or placebo in the first viral upper re-
spiratory tract infection and vice versa in the second epi-
sode of the infection. If the criteria for diagnosis of a viral
upper respiratory infection were met, the new drug was
prescribed on daily basis for 1 week at the same dose asTable 2 Relapse rates and cumulative prednisolone dosage a
Intervention group
n = 49
Infection-associated 0.7 ± 0.3 (0.6,1.1)
Relapses (episodes/patient per year)a
Total relapses (episodes/patient per year)a 0.9 ± 0.4 (0.7, 1.2)
Cumulative prednisolone (mg/kg per year)b 120 ± 32 (105,131)
aRelapse rates are the mean incidence density rates ± SD (95% confidence interval)
bThe data are expressed as the means ± SD (95% confidence interval).
-Adapted and reproduced with permission from Gulati et al. Clin J Am Soc Nephrol 6:6that of the prednisolone being taken by the patient on
alternate-day basis. The relapse rate after viral upper re-
spiratory infection was 48% in the placebo group and 18%
in the prednisolone group. Although all the three studies
had some methodological flaws, they were all randomized
controlled trials with adequate baseline similarities bet-
ween groups, and they all demonstrated that a 5 to7-day
course of daily prednisolone as the intervention during in-
fectious triggers of relapse significantly reduced the risk of
relapse; making it an easy treatment option which would
be cost-effective compared to treating multiple relapses.
Zinc supplementation is another interventional meas-
ure noted to reduce relapse rates in patients with SSNS;
reported in two randomized controlled trials.
In the double-blind randomized study in India [54], 81
patients with SSNS, aged 1–16 years were stratified into
frequent relapsers (n = 52) and infrequent relapsers
(n = 29). They were randomized to receive 12-months oft 12-month follow-up
Control group Rate p
n = 46 Difference
1.4 ± 0.5 (1.2,1.9) 0.7 (0.3,1.1) <0.01
1.8 ± 0.5 (1.4, 2.2) 0.9 (0.4, 1.4) <0.0001
Mean
Difference
138 ± 22 (112,144) 16 (−26, 38) 0.3
.
3–69, January, 2011.
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(10 mg/day) (n = 40) or placebo (n = 41). Patients with
frequent relapses also received long-term, alternate-day
prednisolone. Subjects receiving zinc showed a 20%
lower frequency of relapses with 44.7% of the patients
having sustained remission compared to 27.5% in the
placebo group. Patients with frequent relapses receiving
zinc showed a 28% reduction in relapse rates and a sig-
nificantly higher likelihood of sustained remission. Simi-
larly, in another randomized-controlled trial recently
conducted in Pakistan [55], two groups of 60 nephrotic
children aged 2 to 15 years who received zinc supple-
ments and placebo for 6 months were compared. Des-
pite similar pre-study relapses and zinc levels in both
groups, the post-study relapses in zinc group were lower
(28%) compared to the placebo group (34.5%). In
addition, the relapse rate reduction was 43% after zinc
supplementation compared to 27% reduction in placebo
group. With respect to adverse reactions, metallic taste
was observed in 10% of cases.
Conclusions
For pediatricians and pediatric nephrologists, there is a
strong evidence to institute relapse-specific interventions
in children with SSNS. Despite the generally good prog-
nosis of the disease in children, the associated frequent re-
lapses may lead to increased morbidity and potentially
fatal outcomes. For more than 5 decades, corticosteroids
have remained the mainstay of treatment for children with
nephrotic syndrome especially those with MCN although
their target cell or mechanism of action in nephrotic syn-
drome is not clearly understood [29]. Nevertheless, the
recognition of the crucial role of podocyte injury in neph-
rotic syndrome has resulted in many new studies which
have identified several important molecular pathways that
can regulate podocyte injury; giving new evidence that in-
dicates that the disease results from podocyte dysfunction
[29]. Development of drugs which can affect these path-
ways holds prospects for targeted and effective treatments
for nephrotic syndrome in future.
The new discoveries however do not preclude the need
for the use of immunosuppressive agents like corticoste-
roids or CsA since these drugs also directly affect podocyte
structure and function. Thus, the KDIGO recommenda-
tion of prescribing daily prednisolone during episodes of
upper respiratory infections remains a relevant interven-
tion aimed to reduce the risk of relapse. In tandem with
this recommendation is the use of zinc supplements which
reduces both the frequency of respiratory tract infections
and relapse rates. Prompt search and treatment for UTI
should not be overlooked by clinicians managing children
with nephrotic syndrome. These relapse-specific interven-
tions can reduce the morbidity associated with frequent
relapses and ultimately improve the child’s quality of life.Abbreviations
CsA: Cyclosporine A; FSGS: Focal segmental glomerulosclerosis;
HLA: Histocompatibility antigen; ISKDC: International Study of Kidney Disease
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change nephropathy; MMF: Mycophenolate mofetil; SRNS: Steroid-resistant
nephrotic syndrome; SSNS: Steroid-sensitive nephrotic syndrome; UTI: Urinary
tract infection.
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